Baillie Gifford & CO Denali Therapeutics Inc. Transaction History
Baillie Gifford & CO
- $128 Billion
- Q2 2025
A detailed history of Baillie Gifford & CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 11,955,323 shares of DNLI stock, worth $158 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
11,955,323
Previous 12,090,040
1.11%
Holding current value
$158 Million
Previous $164 Million
1.72%
% of portfolio
0.13%
Previous 0.15%
Shares
31 transactions
Others Institutions Holding DNLI
# of Institutions
244Shares Held
134MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$174 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$156 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$87 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$82.8 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA5.66MShares$74.9 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $1.77B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...